OP
CARM

ORG Partners’s Carisma Therapeutics CARM Stock Holding History

ORG Partners’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8 Hold
200
– – ﹤0.01% 1698
2025
Q3 		$54 Hold
200
– – ﹤0.01% 1558
2025
Q2 		$80 Hold
200
– – ﹤0.01% 1496
2025
Q1 		$46 Hold
200
– – ﹤0.01% 1366
2024
Q4 		$83 Hold
200
– – ﹤0.01% 1255
2024
Q3 		$196 Hold
200
– – ﹤0.01% 1103
2024
Q2 		$334 Buy
+200
New +$298 ﹤0.01% 1674
2024
Q1 		– Sell
-200
Closed -$586 – 614
2023
Q4 		$586 Hold
200
– – ﹤0.01% 1038
2023
Q3 		$846 Hold
200
– – ﹤0.01% 1158
2023
Q2 		$1.68K Buy
+200
New +$1.09K ﹤0.01% 1214

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ORG Partners's CARM Position: Q4 2025 in Review

ORG Partners held its Carisma Therapeutics (CARM) position steady in Q4 2025 at 200 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #1698.

ORG Partners first reported a position in CARM in Q2 2023 and has held it in 10 quarters since. The position peaked at $1.68K in Q2 2023. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • ORG Partners held 200 shares of Carisma Therapeutics worth $8 as of Q4 2025.
  • ORG Partners left its Carisma Therapeutics share count unchanged in Q4 2025.
  • Carisma Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1698 holding.
  • ORG Partners first reported a position in Carisma Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • ORG Partners's Carisma Therapeutics position peaked at $1.68K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.